Syndevrx Inc
Syndevrx Inc., based in Cambridge, MA, is a pioneering company in the emerging field of metabo-oncology, focusing on the intersection of obesity and cancer treatment. The company is developing its lead compound, Evexomostat SDX-7320, to address the critical need for therapies targeting metabolic hormone dysfunction in cancer patients.
Their approach recognizes that dysregulated metabolic hormones significantly contribute to cancer progression and treatment resistance. By targeting these underlying metabolic issues, Syndevrx aims to enhance the effectiveness of standard cancer treatments and improve outcomes for patients affected by both cancer and metabolic disorders.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
